Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis

Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis

Yuya Seko,1 Taichiro Nishikawa,1 Atsushi Umemura,1 Kanji Yamaguchi,1 Michihisa Moriguchi,1 Kohichiroh Yasui,1 Mayumi Kimura,2 Hiroaki Iijima,3 Toshio Hashimoto,3 Yoshio Sumida,4 Takeshi Okanoue,5 Yoshito Itoh1 1Department of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine,...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Seko Y, Nishikawa T, Umemura A, Yamaguchi K, Moriguchi M, Yasui K, Kimura M, Iijima H, Hashimoto T, Sumida Y, Okanoue T, Itoh Y
Format: article
Langue:EN
Publié: Dove Medical Press 2018
Sujets:
canagliflozin
Japanese
NASH
fibrosis stages
SGLT2 inhibitor
type 2 diabetes mellitus
Specialties of internal medicine
RC581-951
Accès en ligne:https://doaj.org/article/bfba1e10d95f4001b5ead934038fdfe6
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/bfba1e10d95f4001b5ead934038fdfe6

Documents similaires